RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
  AIDS
  Anthrax
  Dengue
  Ebola
  HCV
  Influenza
  Leishmaniasis
  Malaria
  MRSA
  Mumps
  Pertussis
  Prion Diseases
  SARS
  Shigella
  Small Pox
  Tuberculosis
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
SARS Channel

subscribe to SARS newsletter
Latest Research : Infectious Diseases : SARS

   EMAIL   |   PRINT
Researchers probe papain-like-protease (PLpro) enzyme that may lead to new SARS drugs

Apr 5, 2006 - 2:14:00 PM , Reviewed by: Priya Saxena
According to the World Health Organization, 8,098 people worldwide were diagnosed with SARS during the 2003 outbreak; 774 died. There were 29 cases reported in the United States, with no fatalities.

 
[RxPG] Researchers at the University of Illinois at Chicago and two other institutions have unraveled the structure of an important new drug target from the virus that causes SARS, severe acute respiratory syndrome.

"By unlocking the three-dimensional structure of this enzyme -- known as papain-like-protease (PLpro) -- we now have a molecular road map to design new drugs that could potentially treat SARS-infected patients, or perhaps patients suffering from other SARS-related illnesses such as the common cold, bronchitis or pneumonia," said Andrew Mesecar, associate professor of pharmaceutical biotechnology in the UIC College of Pharmacy. "We are attempting to use the same approach that has been accomplished in designing effective drugs against HIV protease, which has led to the development of new drugs to fight the AIDS virus."

The research is published in the March 27 issue of the Proceedings of the National Academy of Sciences.

Mesecar said that the knowledge gained from this new atomic structure -- the first-ever reported on this class of proteases -- has the potential to go beyond the treatment of patients infected with the coronavirus that causes SARS.

Coronaviruses, which produce upper respiratory tract infections, were discovered in the late 1960s. The viruses are responsible for 10 percent to 30 percent of all common colds. Recently, two new coronaviruses -- NL63 and HKU1 -- were found to cause many cases of severe pneumonia in children and the elderly throughout the world, he said.

"NL63 and HKU1 infections are severe and often lead to hospitalization," Mesecar said. "It is believed these viruses have been around a long time, but only recently have we developed the technology to identify and detect them. The SARS outbreak and quick response of the scientific community has led to the rapid development of such technology."

SARS was first reported in Asia in early 2003. Over the next several months the illness spread to more than 29 countries in North and South America, Europe and Asia before it was contained. It begins with a high fever, headache and body aches. About 10 percent to 20 percent of patients have diarrhea, and after two to seven days, a dry cough may develop. Most patients develop pneumonia. The infection spreads by close personal contact, often through coughing or sneezing.

According to the World Health Organization, 8,098 people worldwide were diagnosed with SARS during the 2003 outbreak; 774 died. There were 29 cases reported in the United States, with no fatalities.

The papain-like-protease enzyme is essential for viral replication and infection of all of the coronaviruses involved in upper respiratory infections. Eliminating the enzyme should stop the infection, Mesecar said.

During the UIC study, graduate student Kiira Ratia, a member of Mesecar's research team, used X-ray crystallography, a technique that involves bombarding a crystalline form of the enzyme with an intense beam of X-rays that are bent by atoms in the molecules to unlock the details of the molecular structure. The X-ray studies were conducted at Argonne National Laboratory's Advanced Photon Source.

As the X-rays leave the crystal, a unique pattern is created on an ultra-high resolution charge-coupled device camera, a sensor for recording images often used in digital photography and astronomy. The images were then interpreted by computer to reconstruct the positions of all the component atoms.

"We have already discovered compounds that can bind to these pockets and inhibit the activity of this enzyme," Mesecar said. "We have made remarkable progress in a short period of time in generating lead drug-like compounds against the enzyme."



Publication: The research is published in the March 27 issue of the Proceedings of the National Academy of Sciences.
On the web: www.uic.edu 

Advertise in this space for $10 per month. Contact us today.


Related SARS News
A Macaque Model of SARS
Researchers probe papain-like-protease (PLpro) enzyme that may lead to new SARS drugs
Benzotriazole Esters Based Enzyme inhibitors block replication of SARS virus
SARS Can Infect Brain Tissue
Cinanserin May Offer New Hope in Treating SARS
A Prototype drug for SARS
Immune Response Differs in SARS Patients

Subscribe to SARS Newsletter

Enter your email address:


 Additional information about the news article
The research was funded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

In addition to Ratia, other authors included Bernard Santarsiero of UIC; Kumar Saikatendu and Raymond Stevens of the Scripps Research Institute in La Jolla, Calif., and Naina Barretto and Susan Baker of Loyola University Chicago Stritch School of Medicine.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)